Gastroesophageal reflux disease in noncardiac chest pain: Clinical characteristics and PPI test

위식도역류질환과 비심인성 흉통: 임상적 특징과 PPI 치료의 의의

  • Kim, Jeong-Hwan (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Rhee, Poong-Lyul (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 김정환 (건국대학교 의학전문대학원 내과학교실) ;
  • 이풍렬 (성균관대학교 의과대학 내과학교실)
  • Published : 2010.07.01

Abstract

Gastroesophageal reflux disease (GERD) is the most common cause of noncardiac chest pain (NCCP) and is present in up to 60% of patients with NCCP in the West. In Korea, GERD is reported to cause 41% of cases of NCCP, after a reasonable cardiac evaluation. In a recent prospective study in Korea, an empirical trial of a proton pump inhibitor (PPI) was diagnostic for patients with GERD-related NCCP, as elsewhere in the world, and its optimal duration was reported to be at least two weeks in Korea, which is unlike the situation in the West. The report of Choi et al. showed that about 40% of NCCP in non-erosive reflux disease patients had esophageal disorders, including GERD and esophageal motility disorders, and that the standard dose or a low dose of PPI was effective for managing GERD-related NCCP. However, the retrospective nature of the study has limitations, such as an insufficient systemized symptom analysis and the standardization of the dose and interval of the PPI. A large-scale prospective study is needed to assess the accurate diagnosis and effective treatment of NCCP.

Keywords

References

  1. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 112:1448-1456, 1997 https://doi.org/10.1016/S0016-5085(97)70025-8
  2. Richter JE. Chest pain and gastroesophageal reflux disease. J Clin Gastroenterol 30(3 Suppl):S39-S41, 2000
  3. Kim JH, Rhee PL, Park EH, Son HJ, Kim JJ, Rhee JC. Clinical usefulness of subgrouping of patients with non-cardiac chest pain according to characteristic symptoms in Korea. J Gastroenterol Hepatol 22:320-325, 2007 https://doi.org/10.1111/j.1440-1746.2006.04264.x
  4. Wong WM, Lai KC, Lau CP, Hu WH, Chen WH, Wong BC, Hui WM, Wong YH, Xia HH, Lam SK. Upper gastrointestinal evaluation of Chinese patients with non-cardiac chest pain. Aliment Pharmacol Ther 16:465-471, 2002 https://doi.org/10.1046/j.1365-2036.2002.01217.x
  5. Fass R, Fennerty MB, Ofman JJ, Gralnek IM, Johnson C, Camargo E, Sampliner RE. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology 115:42-49, 1998 https://doi.org/10.1016/S0016-5085(98)70363-4
  6. Wang WH, Huang JQ, Zheng GF, Wong WM, Lam SK, Karlberg J, Xia HH, Fass R, Wong BC. Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain?: a meta-analysis. Arch Intern Med 165:1222-1228, 2005 https://doi.org/10.1001/archinte.165.11.1222
  7. Kim JH, Sinn DH, Son HJ, Kim JJ, Rhee JC, Rhee PL. Comparison of one-week and two-week empirical trial with a high-dose rabeprazole in non-cardiac chest pain patients. J Gastroenterol Hepatol 24:1504-1509, 2009 https://doi.org/10.1111/j.1440-1746.2009.05859.x
  8. Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, Johnson SP, Allen J, Brill JV. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 135:1383-1391, 1391.e1-5, 2008 https://doi.org/10.1053/j.gastro.2008.08.045
  9. Rhee PL. Treatment of noncardiac chest pain. J Gastroenterol Hepatol 20(Suppl):S18-S19, 2005
  10. Lee H, Kim JH, Son HJ, Kim JJ, Rhee JC, Suh YJ, Kim S, Rhee PL. Efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Am J Gastroenterol 2010 [Epub ahead of print]